Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Muzastotug · ADG126

Monoclonal antibody · Antagonist of CTLA-4 · developed by Adagene

Phase 2 Most advanced trial

ADAG Developer

2 Registered trials

What is Muzastotug?

Muzastotug is a human monoclonal antibody with a masked binding site directed against CTLA-4 on T cells. Upon activation in the tumor microenvironment, it binds CTLA-4 and inhibits its downregulation of T-cell activation, promoting cytotoxic T-lymphocyte-mediated immune responses against cancer cells. It is studied in locally advanced and metastatic solid tumors including colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ADG126
Drug type: Monoclonal antibody
Targets: CTLA-4
Mechanism: Antagonist of CTLA-4
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: Adagene Inc (ADAG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 4L1XJF3HGL

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06846268	Phase 2	Locally Advanced Colorectal Cancer	Recruiting	ADAG
NCT04645069	Phase 1/2	Advanced/Metastatic Solid Tumors	Completed	ADAG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced Colorectal CancerAdvanced/Metastatic Solid Tumors

Other drugs acting on CTLA4

Ipilimumab FDA approved Tremelimumab FDA approved Botensilimab Phase 2/3 Cadonilimab Early Phase 1 Firastotug Phase 1 Pembrolizumab/Quavonlimab Phase 1/2 Volrustomig Phase 3 Zalifrelimab Phase 1/2

More from Adagene

ADG106 Phase 1/2 ADG206 Phase 1 Firastotug Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADAG page.

Follow ADAG, the company behind Muzastotug

See ADAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADAG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z